GF 15

GF 15 is a potent inhibitor of centrosomal clustering in tumor cells.

Signaling Pathways >> Others >> Others

Research Areas >> Cancer

Centrosomal clustering[1]

GF 15 leads to multipolar mitosis induction with an EC50 of 900 nM. GF 15 exhibits potent cytotoxicity in a concentration-dependent manner against a broad spectrum of tumor cell types including colon, cervix, glioblastoma, pancreas, leukemia, and myeloma-derived cell lines with IC50s of 1-5 μM[1].

Treatment of mouse xenograft models of human colon cancer and multiple myeloma with GF 15 results in tumor growth inhibition and significantly prolonged survival[1].

Hela cells are treated with GF 15 (0, 0.25, 0.5, 0.75, 1, 1.25 μM) for 24 and/or 48 hours. Cell viability is examined using the MTT assay[1].

Mice[1] Beige-nude Xid mice are inoculated s.c. in the right flank with 3×106 OPM2 or HT29 cells. When a tumor is measurable, mice are assigned to a GF 15 treatment group (20, 100 mg/kg) or the control group for 0-20 days. Tumor burden is measured every alternating day using an electronic caliper.

[1]. Raab MS, et al. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2012 Oct 15;72(20):5374-85.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline